patient subgroup...
Age < 65y (younger) Age > 65y Asian type ECOG 0 ECOG 1 EGFR mutation Ex19del EGFR mutation L858R Gender, female Gender, male metastasis (brain) NO metastasis (brain) YES previous systemic treatment (%) previous systemic treatment NO (%) smoker (current or former) smoker (never) stage I stage II stage IIIa
Top evidence (RCT only, high risk of bias excluded)
Best available evidence (possibly low or very low)
All RCTs
All studies (RCT+OBS)
lung cancer : non small cell (NSCLC), ... , meta-analysis of study results
Outcome
Relative effect 95%CI
LoD
Trt. better when
I2
k (RCT/OBS)
Bayesian probability
Overall ROB
Publication bias
Degree of certainty
Endpoint importance
Published MA
efficacy endpoints 00 deaths (OS) 0.74 [0.60, 0.91]< 1 0% 5 studies (5/-) 99.7 % some concern not evaluable moderate crucial - progression or deaths (PFS) 0.35 [0.24, 0.51]< 1 69% 4 studies (4/-) 100.0 % some concern not evaluable moderate important - RFS/DFS 0.20 [0.14, 0.29]< 1 0% 1 study (1/-) 100.0 % NA not evaluable important - DCR 3.52 [2.20, 5.64]> 1 0% 2 studies (2/-) 100.0 % some concern not evaluable moderate non important - events or deaths (EFS) 0.17 [0.11, 0.26]< 1 0% 1 study (1/-) 100.0 % NA not evaluable non important - objective responses (ORR) 4.04 [1.27, 12.87]> 1 92% 4 studies (4/-) 99.1 % some concern not evaluable moderate non important - safety endpoints 00 AE (any grade) 1.41 [0.37, 5.45]< 1 67% 4 studies (4/-) 30.9 % some concern not evaluable moderate non important - AE (grade 3-4) 0.39 [0.18, 0.84]< 1 79% 3 studies (3/-) 99.2 % some concern not evaluable moderate non important - AE leading to death (grade 5) 0.73 [0.31, 1.76]< 1 0% 4 studies (4/-) 75.5 % low not evaluable high non important - AE leading to treatment discontinuation (any grade) 1.67 [0.30, 9.31]< 1 94% 2 studies (2/-) 27.9 % low not evaluable high non important - SAE (any grade) 0.80 [0.54, 1.17]< 1 0% 2 studies (2/-) 87.6 % low not evaluable high non important - TRAE (any grade) 0.46 [0.34, 0.62]< 1 0% 3 studies (3/-) 100.0 % low not evaluable high non important - TRAE (grade 3-4) 0.12 [0.07, 0.22]< 1 0% 2 studies (2/-) 100.0 % some concern not evaluable moderate non important - TRAE leading to death (grade 5) 0.99 [0.02, 50.39]< 1 0% 1 study (1/-) 50.3 % NA not evaluable non important - AE (grade 3-4) endpoints 00 Cough AE (grade 3-4) 1.20 [0.07, 19.77]< 1 0% 2 studies (2/-) 44.9 % some concern not evaluable moderate non important - Decreased appetite AE (grade 3-4) 4.09 [0.18, 91.02]< 1 0% 1 study (1/-) 19.0 % NA not evaluable non important - Dermatitis acneiform AE (grade 3-4) 1.02 [0.02, 51.45]< 1 0% 1 study (1/-) 49.7 % NA not evaluable non important - Diarrhoea AE (grade 3-4) 3.61 [0.36, 35.93]< 1 30% 2 studies (2/-) 13.8 % some concern not evaluable moderate non important - Dry skin AE (grade 3-4) 1.76 [0.13, 23.39]< 1 0% 2 studies (2/-) 33.6 % some concern not evaluable moderate non important - Pruritus AE (grade 3-4) 1.20 [0.07, 19.77]< 1 0% 2 studies (2/-) 44.9 % some concern not evaluable moderate non important - Stomatitis AE (grade 3-4) 5.91 [0.57, 61.41]< 1 0% 2 studies (2/-) 7.0 % some concern not evaluable moderate non important -
LoD: level of statistical demonstration: Statistically conclusive: statistically significant with a strict control of overall risk of type 1 error (statistically demonstrated), does not take into account the risk of bias;
suggested: nominally statistically significant but without a strict control of overall risk of type 1 error;
inconclusive: not nominally statistically significant;
safety concerns;
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies;
published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE.
Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.